Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.43 |
| ▸ | HTR2C | P28335 | 11/20 | 0.43 |
| ▸ | JAK2 | O60674 | 6/20 | 0.38 |
| ▸ | JAK1 | P23458 | 6/20 | 0.38 |
| ▸ | TYK2 | P29597 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942635 | 0.84 | HTR2A (0.54) | HTR2AHTR2C | |
| SCHEMBL15428695 | 0.78 | HTR2B (0.44) | HTR2AHTR2CJAK2JAK1 | |
| SCHEMBL17271442 | 0.77 | F11 (0.34) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL403864 | 0.76 | CYP3A4 (0.46) | HTR2AHTR2CJAK2JAK1TYK2 | |
| SCHEMBL22815040 | 0.76 | F11 (0.34) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL17363397 | 0.72 | RECQL (0.42) | HTR2AHTR2CJAK2JAK1 | |
| SCHEMBL17271565 | 0.71 | JAK2 (0.51) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL12505439 | 0.70 | MAPT (0.52) | — | |
| SCHEMBL29958589 | 0.70 | MAPT (0.52) | — | |
| SCHEMBL17271432 | 0.69 | JAK2 (0.36) | JAK2JAK1TYK2JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322661-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | HTR2A 3604/4885HTR2C 2450/4885JAK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.